Literature DB >> 17999868

Beta-blockers: no longer an option for uncomplicated hypertension.

Sripal Bangalore1, Gayathri Kamalakkannan, Franz H Messerli.   

Abstract

Traditionally, beta-blockers, used as first-line agents to treat uncomplicated hypertension, were recommended by national and international guidelines despite a paucity of evidence regarding their cardiovascular benefit. However, evidence from recent trials and meta-analyses has questioned the use of beta-blockers as preferred agents. This article reviews the data available from clinical trials and argues that beta-blockers are less efficacious than other currently available antihypertensive agents for patients with uncomplicated hypertension.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17999868     DOI： 10.1007/BF02938387

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  42 in total

1.  Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis.

Authors:  Nadia Khan; Finlay A McAlister
Journal:  CMAJ       Date:  2006-06-06       Impact factor: 8.262

2.  Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan.

Authors:  Katerina Fountoulaki; Vasilis Dimopoulos; John Giannakoulis; Elias Zintzaras; Filippos Triposkiadis
Journal:  Am J Hypertens       Date:  2005-02       Impact factor: 2.689

3.  A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus.

Authors:  Sripal Bangalore; Sanobar Parkar; Ehud Grossman; Franz H Messerli
Journal:  Am J Cardiol       Date:  2007-08-10       Impact factor: 2.778

Review 4.  How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis.

Authors:  Hazel A Bradley; Charles Shey Wiysonge; Jimmy A Volmink; Bongani M Mayosi; Lionel H Opie
Journal:  J Hypertens       Date:  2006-11       Impact factor: 4.844

5.  Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Authors:  Henry R Black; William J Elliott; Gregory Grandits; Patricia Grambsch; Tracy Lucente; William B White; James D Neaton; Richard H Grimm; Lennart Hansson; Yves Lacourciere; James Muller; Peter Sleight; Michael A Weber; Gordon Williams; Janet Wittes; Alberto Zanchetti; Robert J Anders
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

6.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

7.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.

Authors:  Richard B Devereux; Björn Dahlöf; Eva Gerdts; Kurt Boman; Markku S Nieminen; Vasilios Papademetriou; Jens Rokkedal; Katherine E Harris; Jonathan M Edelman; Kristian Wachtell
Journal:  Circulation       Date:  2004-08-23       Impact factor: 29.690

9.  Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action.

Authors:  Leszek Kalinowski; Lawrence W Dobrucki; Miroslawa Szczepanska-Konkel; Maciej Jankowski; Ludmila Martyniec; Stefan Angielski; Tadeusz Malinski
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

10.  Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review.

Authors:  F H Messerli; E Grossman; U Goldbourt
Journal:  JAMA       Date:  1998-06-17       Impact factor: 56.272
View more
  3 in total

Review 1.  Premise, promise, and potential limitations of invasive devices to treat hypertension.

Authors:  Elizabeth A Martin; Ronald G Victor
Journal:  Curr Cardiol Rep       Date:  2011-02       Impact factor: 2.931

2.  Ivabradine reduces heart rate while preserving metabolic fluxes and energy status of healthy normoxic working hearts.

Authors:  Benjamin Lauzier; Fanny Vaillant; Roselle Gélinas; Bertrand Bouchard; Roger Brownsey; Eric Thorin; Jean-Claude Tardif; Christine Des Rosiers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-21       Impact factor: 4.733

3.  Should β blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities?

Authors:  William J Elliott; W Kurtis Childers
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.